BiotechTube
Tris Pharma

Tris Pharma

Monmouth Junction, United States· Est.
trispharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

Tris Pharma is a commercial-stage biopharmaceutical company with a dual focus on innovative CNS therapeutics and generic drugs. Its core innovation is the LiquiXR® extended-release liquid technology platform, which has generated a portfolio of approved ADHD medications and a pipeline of novel candidates, including the late-stage dual NOP-MOP agonist cebranopadol for pain. The company operates as a private entity with over 500 employees, utilizing partnerships and its commercial infrastructure to advance its mission of solving intractable therapeutic challenges.

ADHDPainAddictionCentral Nervous System (CNS) Disorders

Technology Platform

Proprietary LiquiXR® extended-release liquid drug delivery technology for creating patient-friendly oral solutions and suspensions.

Funding History

2
Total raised:$150M
Debt$100M
Series A$50M

FDA Approved Drugs

1
DEXTROMETHORPHAN POLISTIREXANDAMay 25, 2012

Opportunities

The urgent global need for effective, non-addictive pain therapies presents a massive market opportunity for its lead asset, cebranopadol.
Furthermore, its established platform and commercial footprint in ADHD allow for lifecycle management and expansion into adjacent CNS disorders with high unmet need.

Risk Factors

Clinical development risk for its novel pipeline, particularly cebranopadol's Phase 3 outcomes and regulatory review, is significant.
Intense competition in both the ADHD and pain therapeutic markets and potential challenges in securing market access and reimbursement for new analgesics also pose material risks.

Competitive Landscape

In ADHD, Tris competes with other specialty pharma companies offering extended-release formulations. In pain, it faces competition from large pharma and biotechs developing novel non-opioid analgesics and improved opioid formulations. Its LiquiXR® platform provides differentiation in drug delivery against generic and branded competitors.

More companies in Drug Delivery & Formulation →More companies in United States →